Advancing PSP and CBD Research: CurePSP Announces Latest Pathway and Pipeline Grant Recipients
2024-03-14
NEW YORK, March 14, 2024 /PRNewswire/ -- CurePSP has awarded its latest Pathway and Pipeline Grants, totaling approximately $400,000. Recipients of the grants are: Dr. Kathryn Bowles, group leader at University of Edinburgh; Dr. Maura Malpetti, research fellow at University of Cambridge; Dr. Jessica Rexach, assistant professor at UCLA; and Dr. Yang You, assistant professor at Mayo Clinic Jacksonville. The studies will make progress in understanding the basic neurobiology of progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) and in developing biomarkers to improve diagnosis and treatment.
The latest Pathway grants will fund two projects: "Investigating Mitochondrial Dysfunction as an Early Pathogenic Mechanism of Primary Tauopathies, Using MAPT Splicing Mutation iPSC-organoids" by Dr. Kathryn Bowles, and "Defining the Unique Immunogenetic Landscape of PSP Compared to Related Dementias" by Dr. Jessica Rexach.
The newest Pipeline grants will fund two projects: "Blood-based Fingerprints of Neuroinflammation in People with PSP and CBD" by Dr. Maura Malpetti, and "Characterization of Plasma-derived Extracellular Vesicle Proteomics for Biomarker Development of PSP and CBD" by Dr. Yang You.
"Together, these grants reflect CurePSP's commitment to funding junior investigators working in high-priority research areas that will help advance our understanding and treatment of PSP and CBD," said Dr. Jennifer Brummet, associate director of scientific affairs and partnerships at CurePSP. "There is a critical need to improve our understanding of PSP and CBD and to improve diagnosis, and these grants will help move the field forward."
About CurePSP's Research Grants
Pathway and Pipeline Grants provide seed funding to support innovative projects focused on the fundamental neurobiology and mechanisms of tauopathies ("Pathway"), and translational projects focusing on new therapeutics and biomarkers for tauopathies ("Pipeline"). The next deadline for Pathway and Pipeline Grant applications is March 28, 2024. Learn more about our research grants here.
About CurePSP
CurePSP is the leading nonprofit organization dedicated to the awareness, care and cure for three neurodegenerative diseases: progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA). As a catalyst for new treatments and a cure, CurePSP establishes important partnerships and funds critical research internationally. Through its advocacy and support efforts, CurePSP enhances education, care delivery and quality of life for people living with PSP, CBD and MSA and their families. Science, community and hope are at the heart of CurePSP's mission and all its services. CurePSP is a registered 501(c)(3) charity within the United States (EIN: 52-1704978). For more information, please visit www.curepsp.org.
Contact:
Kristophe Diaz, PhD
Executive Director and Chief Science Officer
646-725-1453
[email protected]
SOURCE CurePSP, Inc.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
药物
-
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。